Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
4(20%)
Results Posted
50%(6 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
7
35%
Ph phase_3
5
25%
Ph phase_4
3
15%
Ph phase_1
2
10%

Phase Distribution

2

Early Stage

7

Mid Stage

8

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
2(11.8%)
Phase 2Efficacy & side effects
7(41.2%)
Phase 3Large-scale testing
5(29.4%)
Phase 4Post-market surveillance
3(17.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

4

trials recruiting

Total Trials

20

all time

Status Distribution
Active(4)
Completed(12)
Terminated(2)
Other(2)

Detailed Status

Completed12
Recruiting4
unknown2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
4
Success Rate
92.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (11.8%)
Phase 27 (41.2%)
Phase 35 (29.4%)
Phase 43 (17.6%)

Trials by Status

recruiting420%
completed1260%
terminated15%
unknown210%
withdrawn15%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT03320174Phase 2

Long-Term Safety Study of Tafenoquine

Completed
NCT06575647Phase 4

Vivax Elimination With Tafenoquine (VET) Study

Completed
NCT06207370Phase 2

Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

Recruiting
NCT06478641

Expanded Use in Persistent (B. Microti) Babesiosis

Unknown
NCT06666491Phase 3

An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Recruiting
NCT06148792Phase 3

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

Recruiting
NCT04704999Phase 4

Southeast Asia Dose Optimization of Tafenoquine

Recruiting
NCT04411836Phase 3

Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine

Completed
NCT04984759Phase 4

Tafenoquine and Primaquine in Colostrum and Breast Milk

Withdrawn
NCT05753150

Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand

Completed
NCT05096702

Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Unknown
NCT05081089Phase 2

Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali

Completed
NCT02563496Phase 2

A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria

Completed
NCT02802501Phase 3

Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

Completed
NCT02491606Phase 2

Evaluation of Weekly Tafenoquine

Completed
NCT02216123Phase 3

Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria

Completed
NCT01290601Phase 2

Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults

Terminated
NCT02184637Phase 1

A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate

Completed
NCT01205178Phase 1

G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)

Completed
NCT02488980Phase 2

An Evaluation of Weekly Tafenoquine

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20